Cardiotoxicity publications have been increasing at an astounding pace since the 1970s. If there was a time to be bringing a cardioprotective agent with historic clinical efficacy to market, it is now. 2024 is on track to being another massive year for cardiotoxicity research - hopefully publications relating to Zantrene can be in that mix. For the record, publications on FTO is only 4000.
Cardioprotection thread, page-343
-
- There are more pages in this discussion • 231 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.01 |
Change
0.260(14.9%) |
Mkt cap ! $342.2M | |||
| Open | High | Low | Value | Volume |
| $1.87 | $2.08 | $1.86 | $1.269M | 645.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 505 | $1.98 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.02 | 4543 | 2 |
View Market Depth
| Last trade - 16.10pm 18/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |